# Pequot Capital

> Pequot Capital is a VC fund in Westport backing Health Care, Software and Biotechnology. See 118 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Westport, United States
- Total investments: 118
- Last investment: Sep 2014
- Lead investor: 31%
- Fund size: $725M
- Last fund: Feb 2001
- Last updated: Aug 2026

Pequot Capital is a VC fund in Westport focused on Health Care and Software. Pequot Capital Management, Inc. announced its closing in 2009.Pequot Capital Management, Inc. is a U.S. registered investment adviser founded in 1998 by Arthur J. Samberg, Chairman and Chief Executive Officer, to manage the Pequot Family of Funds, which began trading in 1986. The firm manages approximately $5.0 billion in assets as of September30, 2008 (including approximately $580 million of uncalled committed capital) in multiple strategies. An institutional quality infrastructure and an extensive proprietary research platform supports over 150 employees, with offices in Connecticut, New York, California and London. Pequot Capital offers a diverse range of investment products tailored to the needs of domestic and offshore investors. Their clients include institutions and sophisticated high net worth investors. They continually evaluate their product line and encourage innovation within the firm.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $3.6M–$13M |
| Series B | $9.2M–$41M |
| Series C | $12M–$60M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 21 | 18% |
| Software | 19 | 16% |
| Biotechnology | 16 | 14% |
| Medical Device | 12 | 10% |
| Medical | 9 | 8% |

96 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 24 | 20% |
| Series B | 21 | 18% |
| Series A | 17 | 14% |
| Series D | 17 | 14% |
| Funding Round | 17 | 14% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 68 | 58% |
| Hong Kong | 1 | 1% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AcuFocus | Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons onsurgical placement of the KAMRA.It was founded in 2011 and headquartered in Irvine, California. | $21M |  | Sep 03, 2014 |  |
| AcuFocus | Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons onsurgical placement of the KAMRA.It was founded in 2011 and headquartered in Irvine, California. | $21M | Series G | Sep 03, 2014 |  |
| iBiquity Digital Corporation | IBiquity Digital develops and licenses a digital HD Radio technology for AM and FM audio and data broadcasting in the United States and internationally. Its HD radio technology allows digital radio signals to ride the same airwaves as analog AM and FM radio broadcasts. The company provides a Gigaware Navigation Control HD Radio Receiver accessoryand a Gigaware HD Radio application for iPhone and iPod touch users to receive HD Radio FM broadcasts. iBiquity Digital Corporation was formerly known as USA Digital Radio, Inc. The company was founded in 1991 and is based in Columbia, Maryland, with additional offices in Basking Ridge, New Jersey; and Pontiac, Michigan. | $42.5M | Private Equity | Jul 20, 2009 |  |
| Facet Solutions | Facet Solutions develops surgical devices for the treatment of degenerative spinal disorders. Facet Solutions was founded on 2003 and is based in Hopkinton, Massachusetts. | $4.1M | Debt Financing | Jun 12, 2009 |  |
| Sadra Medical | Sadra Medical is exploring new minimally invasive alternatives to traditional surgical valve replacement. The company hopes that devices allowing such procedural advances will facilitate and enhance treatment of aortic valve disease.Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. Bydeveloping minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass. By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today.Sadra Medical, a subsidiary of Boston Scientific. |  | Series C | May 22, 2009 |  |
| Copan Systems | COPAN Systems, Inc. provides massive array of idle disks storage solutions to unlock the value of long-term persistent data. The company offers virtual tape library products for backup/restore and disaster recovery applications; and archive products to retain digital assets with store and retrieve features at the file level. It offers dataprotection, archive, tiered storage, power and cooling, backup/restore, and disaster recovery solutions. The company’s customers include education, financial, government, healthcare, technology, media, and service provider industries. COPAN Systems, Inc. was founded in 2002 and is headquartered in Longmont, Colorado. | $18.5M |  | Feb 17, 2009 |  |
| MTM Technologies | MTM Technologies has become a strategic partner for organizations of all sizes across numerous verticals. MTM Technologies is a leading national provider of innovative, next-generation, IT solutions designed to empower the modern organization and the users. Partnered with the top-tier technology providers and with offices from coast to coast, theirunique solution-based methodology, combined with their experience and expertise, has enabled thousands of industry-leading organizations to effectively address their business needs, optimize the returns on their IT investments, mitigate risk, and focus on growth and profitability. | $2M | Debt Financing | Feb 13, 2009 |  |
| InfaCare Pharmaceutical | InfaCare Pharmaceutical, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceuticals for the neonatal and pediatric patient population. Its neonatal product, Stanate, is under development for the pharmacologic treatment of infantile jaundice or hyperbilirubinemia. The company was founded in 2005 and isbased in Trevose, Pennsylvania. | $28M | Series B | Oct 28, 2008 |  |
| MTM Technologies | MTM Technologies has become a strategic partner for organizations of all sizes across numerous verticals. MTM Technologies is a leading national provider of innovative, next-generation, IT solutions designed to empower the modern organization and the users. Partnered with the top-tier technology providers and with offices from coast to coast, theirunique solution-based methodology, combined with their experience and expertise, has enabled thousands of industry-leading organizations to effectively address their business needs, optimize the returns on their IT investments, mitigate risk, and focus on growth and profitability. | $6.5M | Debt Financing | Jun 18, 2008 |  |
| EnzymeRx | EnzymeRx! a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role. Our patented formulation of pegylated uricase is designed to have a long half life as well as reduced immunogenicity. | $14M |  | May 28, 2008 |  |

10 of 118 investments shown.

## Co-investors
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 12 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 6 deals together
- [Benchmark](https://shizune.co/investors/profile/benchmark) — VC Fund, 6 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 6 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 5 deals together
- [Constellation Technology Ventures](https://shizune.co/investors/profile/constellation-technology-ventures) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [Finch Capital](https://shizune.co/investors/profile/finch-capital) — VC Fund
- [Logo Ventures](https://shizune.co/investors/profile/logo-ventures) — VC Fund
- [TechOne VC](https://shizune.co/investors/profile/techone-vc) — VC Fund

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Facebook VC Funds](https://shizune.co/investors/facebook-vc-funds)
- [Facebook Investors in United States](https://shizune.co/investors/facebook-investors-united-states)
- [Facebook VC Funds in United States](https://shizune.co/investors/facebook-vc-funds-united-states)
- [Facebook Investors](https://shizune.co/investors/facebook-investors)

## FAQ

### What does Pequot Capital invest in?

Pequot Capital invests primarily in Health Care, Software and Biotechnology startups, most often at Series C and Series B stage. Most of the 118 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Pequot Capital's check size?

Pequot Capital typically joins rounds of $3.6M–$13M at Series A, $9.2M–$41M at Series B and $12M–$60M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pequot Capital participates in.

### When did Pequot Capital last invest?

The most recent investment recorded for Pequot Capital closed in Sep 2014. Shizune tracks 118 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co